Retraction
Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas
Paper Information
Record ID:
45298
Author(s):
Journal:
Publication Date:
October 16, 2021
Retraction Date:
June 12, 2023
(2.4 years years ago)
Subjects:
Institutions:
- Department of Malignant Hematology and Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA
- Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA
- Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA
- Department of Immunology and Malignant Hematology, Tianjin Cancer Hospital, Tianjin 300060, China
- The Drug Discovery, Delivery and Experimental Therapeutics, University of Kansas Cancer Center, Kansas City, KS 66160, USA
- Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Department of Pathology, University of Nebraska Medical Center, Omaha, NE 68198, USA
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
- Department of Pathology, Weill-Cornell Medical College, New York, NY 10065, USA
Countries:
Article Type:
Publisher:
Elsevier - Cell Press
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (277)
277
Total Citations12
Post-Retraction(4.3%)
263
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
1
Within 30 days
8
Within 1 year
0
After 2+ years
644
Days since retraction (latest)
Paper citing Coordinated Silencing of MYC-Mediated miR-29 by HD...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Coordinated Silencing of MYC-Mediated miR-29 by HD...
Unknown Authors
Unknown Journal
Published: Unknown
Identification of a chromatin regulator signature and potential candidate drugs for primary open-angle glaucoma
Xinyue Zhang, Lulu Xiao, Xiaoyu Zhou et al. (8 authors)
Epigenomics
Open Access
Published: Mar 2025
644 days after retraction
YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma
Aránzazu Chamorro-Jorganes, Núria Profitós-Pelejà, Clara Recasens-Zorzo et al. (11 authors)
Neoplasia
Open Access
Published: Feb 2025
1 citation
1 citation
604 days after retraction
Ypel2 Regulates the Efficacy of Brd4-Ezh2 Dual Targeting in Ezh2y641mut Germinal Center-Derived Lymphoma
Gaël Roué, Aránzazu Chamorro-Jorganes, Núria Profitós-Pelejà et al. (11 authors)
Unknown Journal
Published: Jan 2025
569 days after retraction
The study on the mechanism of miR-29a in SPPV infection
Juntao Ding, MA Xiao-qin, Beibei Zhang et al. (9 authors)
Virology
Published: Sep 2024
474 days after retraction
Immune escape of multiple myeloma cells results from low miR29b and the ensuing epigenetic silencing of proteasome genes
Patrizia Leone, Eleonora Malerba, Marcella Prete et al. (13 authors)
Biomarker Research
Open Access
Published: Apr 2024
3 citations
3 citations
316 days after retraction
EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis
Qiuyue Zhang, Yajie Shi, Sen Liu et al. (16 authors)
Cell Reports
Open Access
Published: Feb 2024
9 citations
9 citations
234 days after retraction
The TGFβ2‐Snail1‐miRNA<sub>TGFβ2</sub> Circuitry is Critical for the Development of Aggressive Functions in Breast Cancer
Liyun Luo, Ning Xu, Weina Fan et al. (10 authors)
Clinical and Translational Medicine
Open Access
Published: Feb 2024
4 citations
4 citations
234 days after retraction
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu et al. (8 authors)
Signal Transduction and Targeted Therapy
Open Access
Published: Nov 2023
79 citations
79 citations
147 days after retraction
MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications
Joanna Szczepanek, Andrzej Tretyn
Biomolecules
Open Access
Published: Oct 2023
16 citations
16 citations
138 days after retraction
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and <i>TP53</i>/p53 – a Nordic Lymphoma Group study
Joana Rodrigues, Peter Hollander, Lina Schmidt et al. (16 authors)
Haematologica
Open Access
Published: Aug 2023
5 citations
5 citations
79 days after retraction
Dual role of microRNAs in cancer metastasis
Mahdi Alaee, Pegah Kiyamehr, Faezeh Maroufi et al. (5 authors)
Human Gene
Published: Aug 2023
65 days after retraction
Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases
Bo Han, Mengfei Wang, Jiayi Li et al. (7 authors)
European Journal of Medicinal Chemistry
Published: Jun 2023
19 citations
19 citations
17 days after retraction
Clinical Significance of microRNAs in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
Aneta Sevcikova, Ivana Fridrichová, Nataliia Nikolaieva et al. (7 authors)
Cancers
Open Access
Published: May 2023
16 citations
16 citations
35 days before retraction
The roles of EZH2 in cancer and its inhibitors
Yuankai Liu, Qiong Yang
Medical Oncology
Open Access
Published: May 2023
78 citations
78 citations
37 days before retraction
Molecular classification and therapeutics in diffuse large B-cell lymphoma
Gaelen Shimkus, T. NONAKA
Frontiers in Molecular Biosciences
Open Access
Published: Feb 2023
10 citations
10 citations
129 days before retraction
microRNA-29b-3p attenuates diabetic nephropathy in mice by modifying EZH2
Yurong Zhao, Dandan Li, Ping Zhou et al. (5 authors)
HORMONES
Published: Jan 2023
2 citations
2 citations
139 days before retraction
Tissue-Specific microRNA Expression Profiling to Derive Novel Biomarkers for the Diagnosis and Subtyping of Small B-Cell Lymphomas
Susan Swee-Shan Hue, Jin Yu, Cheng He et al. (9 authors)
Cancers
Open Access
Published: Jan 2023
4 citations
4 citations
153 days before retraction
Epigenetic targets in B- and T-cell lymphomas: latest developments
Marcelo Lima Ribeiro, Salvador Sánchez-Vinces, Laura Mondragón et al. (4 authors)
Therapeutic Advances in Hematology
Open Access
Published: Jan 2023
2 citations
2 citations
162 days before retraction
MicroRNAs in cancer metastasis: biological and therapeutic implications
Marie C. Sell, Charmaine A. Ramlogan‐Steel, Jason C. Steel et al. (4 authors)
Expert Reviews in Molecular Medicine
Open Access
Published: Jan 2023
33 citations
33 citations
162 days before retraction
Molekulare Klassifizierung und Therapien des diffusen großzelligen B-Zell-Lymphoms
Gaelen Shimkus, T. NONAKA
Kompass Onkologie
Published: Jan 2023
162 days before retraction
MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression
Yuki Murakami, Kei Kimura-Masuda, Tsukasa Oda et al. (15 authors)
Genes
Open Access
Published: Dec 2022
6 citations
6 citations
165 days before retraction
Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
Laure Maneix, Polina Iakova, Shannon E. Moree et al. (11 authors)
Cancer Research Communications
Open Access
Published: Dec 2022
5 citations
5 citations
186 days before retraction
Emerin interacts with histone methyltransferases to regulate repressive chromatin at the nuclear periphery
Nicholas Marano, James M. Holaska
Frontiers in Cell and Developmental Biology
Open Access
Published: Oct 2022
7 citations
7 citations
249 days before retraction
Mechanisms Controlling MicroRNA Expression in Tumor
Shipeng Chen, Ya Wang, Dongmei Li et al. (13 authors)
Cells
Open Access
Published: Sep 2022
24 citations
24 citations
272 days before retraction
The Role of miR-29s in Human Cancers—An Update
Thuy T.P. Nguyen, Kamrul Hassan Suman, Thong Ba Nguyen et al. (5 authors)
Biomedicines
Open Access
Published: Aug 2022
21 citations
21 citations
287 days before retraction
MicroRNAs as Regulators of Cancer Cell Energy Metabolism
Natarajaseenivasan Suriya Muthukumaran, Prema Velusamy, Charles Solomon Akino Mercy et al. (6 authors)
Journal of Personalized Medicine
Open Access
Published: Aug 2022
21 citations
21 citations
298 days before retraction
HDAC2- and EZH2-Mediated Histone Modifications Induce PDK1 Expression through miR-148a Downregulation in Breast Cancer Progression and Adriamycin Resistance
Yun-Xia Xie, Zhumei Shi, Ying-Chen Qian et al. (7 authors)
Cancers
Open Access
Published: Jul 2022
10 citations
10 citations
324 days before retraction
Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs.
Pieterjan Ginckels, Paul Holvoet
PubMed
Published: Mar 2022
56 citations
56 citations
468 days before retraction
Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer
Deniz Mortazavi, Behnoush Sohrabi, Meysam Mosallaei et al. (13 authors)
Journal of Oncology
Open Access
Published: Jan 2022
18 citations
18 citations
517 days before retraction
Oxidative Stress Modulation with MicroRNAs in Cancers
Srilekha Avvari, M. Rishitha, K. Sri Manjari et al. (5 authors)
Unknown Journal
Published: Jan 2022
1 citation
1 citation
527 days before retraction
Epigenetic regulation and microRNA expression
Ancuța Jurj, Oana Zănoagă, Cornelia Braicu et al. (4 authors)
Elsevier eBooks
Published: Jan 2022
527 days before retraction
Diffuse large B-Cell lymphoma: from novel molecular classifications to tailored targeted therapies
Jennifer Kimberly Lue, Grzegorz S. Nowakowski
Journal of Cancer Metastasis and Treatment
Open Access
Published: Jan 2022
1 citation
1 citation
527 days before retraction
Histone Modifications and Their Targeting in Lymphoid Malignancies
Miranda Fernández-Serrano, René Winkler, Juliana C. Santos et al. (6 authors)
International Journal of Molecular Sciences
Open Access
Published: Dec 2021
10 citations
10 citations
532 days before retraction
MMP-9 drives the melanomagenic transcription program through histone H3 tail proteolysis
Yonghwan Shin, Sungmin Kim, Nikhil Baban Ghate et al. (5 authors)
Oncogene
Published: Nov 2021
22 citations
22 citations
573 days before retraction
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
Marije J. Voskamp, Shuang Li, Kim Robin van Daalen et al. (6 authors)
Cancers
Open Access
Published: Oct 2021
22 citations
22 citations
593 days before retraction
Novel Natural Inhibitors Targeting Enhancer of Zeste Homolog 2: A Comprehensive Structural Biology Research
Weihang Li, Ziyi Ding, Yunlong Zhao et al. (15 authors)
Frontiers in Oncology
Open Access
Published: Oct 2021
6 citations
6 citations
601 days before retraction
The molecular mechanisms and therapeutic potential of EZH2 in breast cancer
Sara Adibfar, Marischa Elveny, Hadisha Sh. Kashikova et al. (8 authors)
Life Sciences
Published: Oct 2021
35 citations
35 citations
606 days before retraction
The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment
Hepei Yuan, Momoko Nishikori, Yasuyuki Otsuka et al. (6 authors)
Cancer Science
Open Access
Published: Aug 2021
17 citations
17 citations
654 days before retraction
Transcription Factor DLX5 Promotes Hair Follicle Stem Cell Differentiation by Regulating the c-MYC/microRNA-29c-3p/NSD1 Axis
Bojie Lin, Jiangying Zhu, Guo-Qian Yin et al. (8 authors)
Frontiers in Cell and Developmental Biology
Open Access
Published: Jul 2021
4 citations
4 citations
697 days before retraction
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
Nilanjan Adhikari, Tarun Jha, Balaram Ghosh
Journal of Medicinal Chemistry
Published: Jun 2021
49 citations
49 citations
719 days before retraction
Matrine suppresses cell growth of diffuse large B-cell lymphoma via inhibiting CaMKIIγ/c-Myc/CDK6 signaling pathway
Jianyou Gu, Xiao Wang, Ling Zhang et al. (9 authors)
BMC Complementary Medicine and Therapies
Open Access
Published: Jun 2021
6 citations
6 citations
738 days before retraction
A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity
Chin-Cheng Lee, Kuo-Hao Ho, Tzu‐Wen Huang et al. (7 authors)
Life Sciences
Published: Mar 2021
18 citations
18 citations
804 days before retraction
<i>miR-29</i>modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors
Sonali Sharma, Gabriela Mladonická Pavlasová, Václav Šeda et al. (26 authors)
Blood
Open Access
Published: Mar 2021
48 citations
48 citations
805 days before retraction
Gene Transactivation and Transrepression in MYC-Driven Cancers
Marika Scafuro, Lucia Capasso, Vincenzo Carafa et al. (5 authors)
International Journal of Molecular Sciences
Open Access
Published: Mar 2021
28 citations
28 citations
807 days before retraction
A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFG and MYBL2
Olga Vera, Ilah Bok, Neel Jasani et al. (10 authors)
Cancers
Open Access
Published: Mar 2021
27 citations
27 citations
815 days before retraction
Epigenetic Regulation of MicroRNA Clusters and Families during Tumor Development
Jana Gregorová, Petra Vychytilova‐Faltejskova, Sabina Ševčı́ková
Cancers
Open Access
Published: Mar 2021
41 citations
41 citations
818 days before retraction
Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
Arathi Jayaraman, Tong Zhou, Sundararajan Jayaraman
MicroRNA
Published: Mar 2021
2 citations
2 citations
833 days before retraction
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Patrick Nylund, Alba Atienza Párraga, Jakob Haglöf et al. (12 authors)
Cell Death and Disease
Open Access
Published: Feb 2021
16 citations
16 citations
850 days before retraction
Quick Stats
Total Citations:
277
Years Since Retraction:
2.4 years
Open Access:
Yes
Last Checked:
Jul 24, 2025